Abstract: Disclosed are new synthetic compounds that includes a lipid diether to which a sugar group is grafted via a PEG spacer, and to now liposomes including at least one of the compounds. In particular, new synthetic compounds of general formula (I) and to new liposomes including at least one of the compounds is disclosed, as well as new liposomes for use as vectors and/or adjuvants, especially for use in vaccines.

Abstract: A landing gear box is made of composite material panels comprising a skin made of composite material and having two opposite general sides, and first stiffeners extending over one of the sides of the skin. It is characterised in that it comprises additional stiffeners that are arranged on the side of the skin opposite that bearing the first stiffeners, and which extend in a direction distinct from that of the first stiffeners. The skin and the stiffeners arranged on each side are preferably made integral by co-moulding.

Abstract: A pharmaceutical composition comprising at least dendritic cells modified with a molecule selected from the group consisting of: a GILZ protein or a functional fragment of at least 5 consecutive amino acids of said protein; a small interfering RNA (siRNA) targeting the GILZ transcript or an antisense oligodeoxynucleotide complementary to said transcript; and a recombinant expression vector containing a polynucleotide encoding said GILZ protein, said fragment, said siRNA or said antisense oligodeoxynucleotide complementary to said transcript and a pharmaceutically acceptable carrier. In addition, a method for treatment of autoimmune diseases, inflammatory diseases, allergies, transplant rejection and graft-versus-host disease, cancers or pathogenic microorganism infections by administering an effective amount of said pharmaceutical composition to a subject in need thereof.

Abstract: A panel is made of composite material comprising a skin made of composite material and having two opposite general sides, and first stiffeners extending over one of the sides of the skin. It is characterised in that it comprises additional stiffeners that are arranged on the side of the skin opposite that bearing the first stiffeners, and which extend in a direction distinct from that of the first stiffeners. The skin and the stiffeners arranged on each side are preferably made integral by co-moulding.

Abstract: The invention concerns the use of at least one: a) a GILZ protein, a functional fragment of at least 5 consecutive amino acids of said protein, a GILZ modulator, or a recombinant vector expressing same, isolated or expressed in modified dendritic cells, and b) an antigen of interest and/or a molecule allowing targeting and/or passage of the plasmic membrane of dendritic cells, to prepare a medicine for preventing and/or treating autoimmune, inflammatory diseases, allergies, graft rejection and graft-versus-host disease, cancers and pathogenic micro-organism infections.

Abstract: The invention relates to the treatment of a tumor in a patient, by injecting T lymphocytes depleted of regulatory T lymphocytes, and expressing a molecule allowing their specific destruction, the patient receiving beforehand a non-myeloablative or myeloablative lymphopenic treatment.

Abstract: The invention concerns the use of at least one: a) a GILZ protein, a functional fragment of at least 5 consecutive amino acids of said protein, a GILZ modulator, or a recombinant vector expressing same, isolated or expressed in modified dendritic cells, and b) an antigen of interest and/or a molecule allowing targeting and/or passage of the plasmic membrane of dendritic cells, to prepare a medicine for preventing and/or treating autoimmune, inflammatory diseases, allergies, graft rejection and graft-versus-host disease, cancers and pathogenic micro-organism infections.

Abstract: The invention relates to the fields of biology, genetics and medicine. The invention describes methods and compositions enabling (1) the identification of suppressor T cells or lymphocytes (Ts) or the precursors thereof (pTs) for diagnostic or therapeutic purposes and for carrying out genomic or proteomic studies, particularly for the identification of novel markers and/or therapeutic targets for said cells; (2) the production of suppressor T cells or lymphocytes (Ts) or the precursors thereof (pTs) and/or the manipulations thereof in vivo or ex vivo for controlling various pathological conditions, including diseases associated with abnormal activity of effector and/or regulator lymphocytes. The invention relates to the preparation of said compositions based on Ts lymphocytes and pTs, and to the use thereof in cell therapies.

Abstract: Connector consists of a male connector part (40) linked to the tension line (6) and operable to penetrate a female receptacle part (1) being part of the anchoring point and having an upper necked portion (.phi..sub.2) forming an internal circular shoulder (3). The connector comprising a cylindrical body (5) connected to the line and an internal cavity (10) whose cylindrical wall (16) is provided with a circular series of openings (11) to the outside. Each opening receives a dog (12) operable to assume a first, extended position projecting radially beyond the connector wall (16), radially abutting said wall and bearing upon the bottom surface of the opening (11) under the urging of a spring (14) and a second, retracted position during descent of the male connector part due to the pushing of the inclined bottom face (18) of the end of the dog against the mouth (4) of the female receptacle part.